CA-LATTICEFLOW-AI
12.3.2024 12:31:33 CET | Business Wire | Press release
LatticeFlow AI, the leading platform empowering AI teams to build performant, safe, and trustworthy AI solutions, proudly announces the creation of its advisory board and the appointment of two AI luminaries, Milena Marinova and Jean-Luc Chatelain, as founding members.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312894740/en/
LatticeFlow AI welcomes Milena Marinova and Jean-Luc Chatelain to its advisory board (Photo: Business Wire)
Milena Marinova, brings a wealth of experience and expertise in software development and in the field of AI, ML and GenAI, with over 15 years of launching innovative AI products and solutions globally. Most recently she established the AI Acceleration Studio at Microsoft and currently serves as its Vice President. Milena’s visionary leadership in building intelligent AI systems, emphasizing experimentation and evaluation for human and AI collaboration, aligns with LatticeFlow AI’s mission of delivering trustworthy AI solutions at scale.
“In the era of AI adoption, building responsible AI is paramount to the success of these deployments,” says Milena. “I’m happy to become an advisor to LatticeFlow AI and help advance the vision of its founders and their strong commitment to building tools that ensure AI safety and trust.”
Jean-Luc Chatelain, former CTO of Applied Intelligence at Accenture, is also a seasoned AI expert with a deep understanding of the challenges and opportunities in building and operationalizing mission-critical AI systems for large-scale organizations.
“Trust is the foundation of a successful AI platform,” says Jean-Luc. “I am thrilled to join the LatticeFlow AI’s advisory board and help the company realize its mission of enabling enterprises to build and deploy safe and trustworthy AI systems that unlock business value.”
Milena’s outstanding leadership in pioneering groundbreaking AI solutions, coupled with her profound expertise in machine learning, AI, and deep neural networks, will be invaluable in advancing LatticeFlow AI’s vision of bringing mission-critical AI solutions to market. Similarly, Jean-Luc’s expertise in constructing AI systems for large organizations across the globe, grounded in trust and responsibility, will be pivotal in helping LatticeFlow AI bolster the safety and reliability of its solutions.
“We are honored to welcome Milena and Jean-Luc to our advisory board,” shared LatticeFlow AI’s co-founders Petar Tsankov (CEO) and Pavol Bielik (CTO). “Their collective expertise, aligned with our vision for responsible AI adoption, will be instrumental in guiding our long-term growth strategy in the years to come.”
The creation of LatticeFlow AI’s top-tier AI advisory board follows the expansion of LatticeFlow AI into the US market and the appointment of Tom Ulrich as Senior Vice President and General Manager of LatticeFlow North America.
About LatticeFlow AI
LatticeFlow AI offers a cutting edge AI platform that empowers enterprise teams to build performant, safe, and trustworthy AI at scale. Our platform is designed to unlock the full value of AI by systematically addressing critical model and data issues through automated processes and intelligent workflows across your entire AI lifecycle.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312894740/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom